Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264 ...

Sun-damaged normal skin contains many mutations caused by ultraviolet (UV) radiation. However, the mechanism by which ...

Radiation is one of the most effective ways to kill a tumor. But these therapies are indiscriminate, and they can damage ...

The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.

Scientists have developed a way to deliver radiation just to cancerous cells; the therapy combines a drug to mark the cancer ...

To conclude our interview with Joshua K. Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the ...

Bayer initiates phase I study with SOS1 inhibitor, BAY3498264 in patients with advanced KRAS-mutated tumours: Berlin Saturday, December 14, 2024, 13:00 Hrs [IST] Bayer announced i ...

Demehri, MD, PhD, of the Department of Dermatology and Center for Cancer Immunology at Massachusetts General Hospital, is the ...

AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...

Greater ORR of 55.6% was seen in patients with EGFR sensitizing and T790M double mutations (78% had received third-generation EGFR-TKI treatment in prior lines of therapy). Sunvozertinib was ...